Abstract: IgA1 proteases (IgA1P) from diverse pathogenic bacteria specifically cleave human immunoglobulin A1 (IgA1) at the hinge region, thereby thwarting protective host immune responses. Streptococcus pneumoniae (S. pneumoniae) IgA1P shares no sequence conservation with serine or cysteine types of IgA1Ps or other known proteins, other than a conserved HExxH Zn-binding motif (1604-1608) found in metalloproteases. We have developed a novel expression system to produce the mature S. pneumoniae IgA1P and we have discovered that this form is both attached to the bacterial cell surface and released in its full form. Our data demonstrate that the S. pneumoniae IgA1P comprises two distinct regions that associate to form an active metalloprotease, the first such example of a metalloprotease that can be split in vitro and recombined to form an active enzyme. By capitalizing on this novel domain architecture, we show that the N-terminal region of S. pneumoniae IgA1P comprises the primary binding region for IgA1, although the C-terminal region of S. pneumoniae IgA1P is necessary for cleavage of IgA1. Our findings lend insight into the protein domain architecture of the S. pneumoniae IgA1P and function of this important virulence factor for S. pneumoniae infection.
Introduction
Streptococcus pneumoniae (S. pneumoniae) is a prominent cause of community-acquired pneumonia and meningitis in children and adults in the United States, 1 Europe, 2 and worldwide. 3 Although the introduction of polysaccharide vaccines has decreased the incidence of bacterial pneumonia in industrialized countries over the last decade, such vaccines are directed against only 7-23 of the more than 90 serotypes. 4 Indeed, invasive pneumococcal infection by non-vaccine serotypes in some Western countries has increased by nearly 500% over the past decade. 5 Clearly, this rapid increase in S. pneumoniae infection of non-vaccine serotypes drives the need for a more universal vaccine. Specifically, a vaccine against a stable, immunogenic protein that serves as a virulence factor for S. pneumoniae has been proposed. 4, 6 One such protein is the S. pneumoniae IgA1 protease (IgA1P) that specifically cleaves IgA1, which comprises over 90% of the antibody in the upper and lower respiratory tract where these infections begin. IgA1P is conserved over multiple pneumococcal serotypes as well as in multiple other Streptococcus strains, highlighting its potential as a vaccine target. 7 IgA1P is a critical virulence factor for S. pneumoniae infection because this protease cleaves host IgA1 to support bacterial colonization by enhancing adherence to the host respiratory epithelial cells and block local agglutination of the bacteria by IgA1. [8] [9] [10] [11] Despite the clinical importance of this protein, little is known about the fundamental structural organization and molecular mechanism of IgA1P, an understanding of which would significantly contribute to our molecular understanding of the pathogenesis of S. pneumoniae infections and generation of primary protection to prevent them. Multiple pathogens produce their own unique IgA1Ps, which act through a wide range of catalytic mechanisms, yet serve the same function to cleave host IgA1 and thereby subvert the initial host immune response. IgA1P from Entamoeba histolytica is a cysteine protease, 12 IgA1P from Haemophilus influenzae is a serine protease, 13 whereas IgA1P derived from S. pneumoniae is a metalloproteinase. 14 Such a clear example of convergent evolution highlights the evolutionary utility of an IgA1P in pathogenesis, despite widely divergent primary sequences. 15 Each IgA1P cleaves the hinge region of host IgA1, dissociating the effector Fc region while the IgA1 FAB remains bound to the bacterial surface. This cleavage promotes infection by two mechanisms. First, Fc receptors on neutrophils can no longer recognize the cleaved and released IgA1 Fc to bind and kill the bacterial cells. 16 Second, the IgA1 FAB fragment remaining on the S. pneumoniae cell surface enhances S. pneumoniae binding to epithelial cells 10 and can no longer prevent colonization. 8 Therefore, a better understanding of the S. pneumoniae IgA1P cleaving mechanism is an important step towards developing therapeutic strategies to prevent primary S. pneumoniae colonization and disease. The S. pneumoniae IgA1P shares no sequence homology with any other known metalloproteinase discovered to date, other than a canonical 5 residue Zn-binding motif comprising residues 1604-1608 (HExxH). This motif contains two of the three residues known to coordinate the catalytic Zn, i.e., H1604 and H1608, but the third Zn-coordinating residue still remains unidentified. 7 In this study, we first show that IgA1P present on the pneumococcal bacterial surface is also released from S. pneumoniae cells with cleavage activity towards its IgA1 substrate. By developing a novel expression and purification system, we have discovered that the S. pneumoniae IgA1P can be recombinantly purified as two separate and individually inactive folded polypeptides that can be combined in trans to form an active protease. We further find that the N-terminal domain is primarily responsible for engaging the substrate, although the C-terminal domain does play a role in facilitating substrate binding and is necessary for IgA1 cleavage. While our studies represent advances in understanding S. pneumoniae IgA1P, which is a novel metalloprotease unlike any other studied to date, the S. pneumoniae IgA1P is the first identified metalloprotease reported that can be split and recombined in trans to form an active enzyme.
Results
Recombinant S. Pneumoniae IgA1P cleaves IgA1 and is identical to the endogenous form
We have utilized a novel recombinant expression system to purify S. pneumoniae IgA1P by employing a dual-tag purification method, which results in a highly pure and active protease [ Fig. 1(A,B) ]. This recombinant construct comprises the active form of S. pneumoniae IgA1P (residues 154-1963) that is covalently attached to the S. pneumoniae cellular surface by sortase-A. 17 To assess the activity of recombinantly purified S. pneumoniae IgA1P from E.coli and confirm its activity as a metalloprotease, IgA1P was incubated with its putative IgA1 substrate and EDTA in a dose-dependent manner utilizing an ELISA-based activity assay described in Materials and Methods [ Fig. 1 . These results are similar to those of a previous study that employed a single N-terminal affinity tag. 19 However, in using a single affinity tag, the authors identified multiple fragments upon purification and concluded that the S. pneumoniae IgA1P was highly susceptible to auto-proteolysis. Thus, use of a dual affinity tag allows for purification of a highly homogeneous single polypeptide that we have found to be stable upon purification.
To compare the recombinant S. pneumoniae IgA1P to its endogenous forms, S. pneumoniae cells and culture media were collected for detection of endogenous IgA1P. Of note, the recombinant IgA1P exhibited the same molecular weight as the endogenous S. pneumoniae IgA1P in both the context of the cell and that released into the cultured media [ Fig. 1(E) ]. Additionally, both the endogenous and recombinant forms exhibit cleavage activity towards IgA1 antibody [ Fig. 1(F) ]. Thus, the S. pneumoniae IgA1P is indeed a metal-dependent metalloprotease, as predicted, and identical to its endogenous counterparts. This is also the first study to show that the fully mature form of S. pneumoniae IgA1P, which comprises residues 154-1963, is released from the S. pneumoniae cell surface and retains its activity of IgA1 cleavage.
S. Pneumoniae IgA1P comprises a well-folded C-terminal domain
Considering the relatively large size of the mature S. pneumoniae IgA1P of residues 154-1963, we reasoned that this protease comprises multiple subdomains. To explore this possibility, limited proteolysis and mass spectrometry were used to identify particular regions of S. pneumoniae IgA1P that are relatively protected from cleavage by exogenous proteases compared with neighboring regions. Regions that are protected from proteolysis result in definitive bands on a denaturing gel, which are then further processed via in-gel digestion to identify peptides within these excised gel bands. Thus, wellprotected regions of S. pneumoniae IgA1P would result in better sequence coverage via mass spectrometry analysis. Our data suggest that regions of S. pneumoniae IgA1P are well protected from proteolysis [ Fig. 2(A) ], including the C-terminal region of residues 1593-1963 that comprises the conserved HExxH motif (residues 1604-1608). Recombinant purification of this C-terminal domain, IgA1P , results in a highly stable polypeptide. Thus, considering that this region comprises the only conserved residues that we have proven to be critical for cleavage of the IgA1 substrate and that this polypeptide is highly stable, we initially hypothesized that it is the C-terminal region that is responsible for metalloprotease enzymatic activity. However, this C-terminal polypeptide of residues 1593-1963, IgA1P , was found to comprise only part of the active site, as additional data below show.
Beginning from IgA1P 1593-1963 , we systematically trimmed this polypeptide from both the N-and Ctermini in order to determine the minimum sequence necessary for proper folding of the Cterminal domain. Specifically, we utilized our limited proteolysis/mass spectrometry data as a guide and nuclear magnetic resonance (NMR) spectroscopy as a tool to assess whether constructs were well folded. NMR spectroscopy is a highly sensitive means to monitor the chemical environment of nuclei, with well-folded proteins exhibiting a high degree of resonance dispersion (i. Chi et al.
monitors a-helical structure [ Fig. 2 able to form a functional protease, as evidenced by cleavage of IgA1 [ Fig. 3(A) ]. Additionally, these two separate domains bind each other as evidenced by both an ELISA-based binding assay [ Fig. 3 Glu is normally 20-120 residues C-terminal of the HExxH motif, thereby placing it within the Cterminally folded IgA1P 1612-1963 domain. Several candidates within S. pneumoniae IgA1P are well conserved between Streptococcus strains, including Glu1628, Glu1661, Glu1695, and Glu1698. 7 In order to determine which Glu is the coordinating residue, each was mutated to Ala and the purified proteins were tested for proteolytic activity [ Fig. 3(B) ]. Cleavage at multiple time points clearly showed once again that mutation to the catalytic base within the conserved HExxH motif, E1605A, completely abrogates activity [ Fig. 3(B) ], consistent with results in the ELISA-based activity assay [ Fig. 1(D) ]. Additionally, these experiments suggest that E1628 is the third Zn coordinating residue, since the E1628A mutant was significantly impaired in IgA1 cleavage whereas the other mutations have no functional effects [ Fig. 3 Fig. 4(A), 4(B) ]. These data suggest that contacts within the isolated C-terminal domain are not strong enough to maintain substrate binding when this domain is alone, but that this region still enhances substrate binding in the context of the primary binding region of residues 154-1611. As would be expected, the active protease (IgA1P ) that cleaves IgA1 between the Fc and FAB region binds only weakly to its cleaved Fc and FAB products, likely to prevent substrate inhibition. To corroborate these results, concentrationdependent ELISAs were conducted using the antiIgA1 Fc as the detection Ab [ Fig. 4(C) ]. The binding of full-length E1605A-IgA1P to the IgA1 substrate is saturated over this range, thereby allowing for the calculation of a pseudo-dissociation constant of 1 nM determined using a single binding isotherm fit. In conrast to the catalyticall inactive E1605A-IgA1P and the 
Discussion
We have elucidated the molecular and functional determinants of a virulence factor of S. pneumoniae, IgA1P, which are critical for its metalloprotease activity. This metalloprotease appears unique in its ability to be capable of being split into two inactive polypeptides in vitro that regain activity in trans. We also show for the first time that the S. pneumoniae IgA1P is released from S. pneumoniae in its active form that retains cleavage activity towards IgA1. Although the serine IgA1P's derived from Gram-negative bacteria (e.g., Haemophilus influenzae, Neisseria gonorrhoeae, and Neisseria meningitidis) are all actively secreted, pneumococcal IgA1P is not actively secreted. 23 Previous investigations have not observed IgA1P release from S. pneumonia, 17 but our ability to detect the protease in the media is likely due to our development of a sensitive new S. pneumoniae IgA1P-specific murine monoclonal antibody (see Materials and Methods). Thus, we have shown that S. pneumoniae IgA1P is both attached to the cell surface and released from S. pneumoniae cells, likely upon autolysis rather than actively secreted. Although several proteins have been discovered to retain their function when expressed as two separate, recombinantly purified polypeptides, which include the tobacco etch virus protease that is a Cys-protease, 21, 22 the S. pneumoniae IgA1P under investigation here is the first metalloprotease that has been shown capable of functioning in such a split manner. Of particular note, several metalloproteases have their catalytic domains split with the insertion of three tandem fibronectin domains, such as the gelatinases MMP-2 and MMP-9. 24 However, in the case of these MMPs, the three Zn coordinating residues are all within the N-terminal part of the catalytic domain. 25 In contrast, the S. pneumoniae IgA1P described here comprises an N-terminal domain that houses the conserved HExxH Zn motif and a separately folded C-terminal domain that houses the proposed third Zn coordinating residue, Glu1628. In general, Zn-dependent proteases use a variety of three residues and a water molecule to tetrahedrally coordinate Zn. 20 For example, metalloproteases such as MMPs utilize three conserved histidine residues, 24 while those of the thermolysin family use two histidine residues and a downstream glutamic acid as the third. 26 Thus, the S. pneumoniae IgA1P is similar to those of the thermolysin family. Indeed, the third glutamic acid, IgA1P E1628, is exactly 20 residues downstream of the conserved HExxH motif just as thermolysin. However, whereas secondary structure predictions indicate that the active site within S. pneumoniae IgA1P comprises b-strands, thermolysin comprises ahelices, which is consistent with no sequence similarity between S. pneumoniae IgA1P and thermolysin. These comparisons suggest that the S. pneumoniae IgA1P is structurally unlike other previously characterized metalloproteases. The studies described herein significantly expand our understanding of this clinically salient protease and lay the groundwork for further atomic resolution studies that may provide candidates for vaccine design.
Materials and Methods

Protein purification
The pJ401 plasmid encoding the entire mature IgA1P residues 154-1963 was commercially purchased from DNA 2.0 (Menlo Park, CA) with an Nterminal 6xHis and C-terminal Maltose Binding Protein (MBP), harboring an N-terminal tobacco etch virus (TEV) cleavage site and C-terminal thrombin cleavage site, respectively. All other constructs were subsequently cloned using this commercially purchased plasmid as a template. 154-1611 and E1605A-IgA1P) were grown at 378C in the presence of 50 lg/mL kanamycin. Protein expression was induced at OD (600 nm) of 0.6 with IPTG at 1 lM final concentration for 4 h at 378C. Cells were harvested and resuspended in Ni buffer (50 mM phosphate buffer, 500 mM NaCl and 10 mM imidazole at pH 7.5). After sonication, the lysate was cleared by centrifugation at 12,000 x g for 15 min at 48C. The supernatant was then applied to a Ni-NTA fast flow column. The protease-containing fractions were collected and applied to an amylose column and the thrombin protease was then used to remove the MBP-tag at room temperature overnight. Protease constructs were further purified by Superdex 200 gel filtration column. All purifications were conducted on an AKTA prime FPLC system (GE Healthcare, Little Chalfont, UK). The C-terminal domain constructs, IgA1P , IgA1P , IgA1P , and IgA1P , were expressed under similar conditions to that described above, however, only a 6xHis tag was used and the final products were refolded, as previously described. 27 The C-terminal MBP used above was found unnecessary to achieve pure and highly stable proteins and we chose to refold this construct, as much of it was initially insoluble. After refolding, the dialysis buffer was changed to Ni buffer and applied to a Ni-NTA fast flow column. Thrombin was subsequently used to remove the His-tag at room temperature overnight. These C-terminal constructs were further purified by Superdex 75 gel filtration column. To purify 
Antibody production
Creation of monoclonal antibody was conducted by injecting 50/50 suspension of antigen with Freuds adjuvant in to Balb C female mice at 100 ug/injection/animal. Each animal has an initial injection followed by two boosts, every 2-3 weeks, 7 days after the 2nd boost the animal is bled. The bleeds were tested by ELISA for titers and also confirmed for activity, the best animal is chosen, 3 days before the fusion the mouse has a final boost of 100 ug of antigen plus PBS, no adjuvant. On the day of the fusion, the mouse was sacrificed and the spleen was removed and pushed through a mesh screen to become a cell culture. The spleen cells were then fused with SP2/0 myeloma cells using PEG fusion protocols. 24 h after the fusion the cells were plated into fifteen to twenty 96 well plates using selective media (IMDM 1 15%FBS 1 AHAT). The cells were grown for a week to 10 days, and then screened by ELISA against the antigen. The positive wells by ELISA screening were expanded and screened for activity. The strongest cultures were immediately cloned by serial dilution, rescreened and subcloned for confirmation of monoclonal. After a stable monoclonal was established, the cells were grown up to large volumes in IMDM 1 10%FBS until they showed 60-70% cell death. The sterile supernatant was harvested and spun at 8000 rpm for 20 min. Supernatant was passed over the appropriate amount of Protein G beads and eluted by low pH buffer. After elution, the Mab peak was dialyzed in PBS overnight for long-term stability and stored at 48.
Limited proteolysis and MS
The recombinant IgA1P samples containing 50 lg of total protein were incubated with trypsin (Promega, Madison, WI) at a 1:200 protein to trypsin ratio for 5 min in room temperature. Reactions were quenched by addition of SDS loading buffer followed by heat denaturation (1008C). Samples were then resolved on a denaturing NuPAGE Bis-Tris 4-12% gradient gel (Thermo Fisher, Grand Island, NY) and indicated bands were excised, in-gel digested with trypsin and analyzed on an LTQ Orbitrap Velos mass spectrometer (Thermo Fisher Scientific, Grand Island, NY) coupled to an Eksigent nanoLC-2D system through a nanoelectrospray LC 2 MS interface. The nano-HPLC system was operated at 3 lL/min for loading onto the trap for 5 min. Afterwards, proteins were eluted at a constant flow rate of 350 nL/ min using a 90-min linear gradient of 2-40% ACN with 0.1% formic acid. LC mobile phase solvents and sample dilutions used 0.1% formic acid in water (Buffer A) and 0.1% formic acid in acetonitrile (Buffer B) (Chromasolv LC-MS grade; Sigma-Aldrich, St. Louis, MO). Data acquisition was performed using the instrument supplied Xcalibur TM (version 2.1)
software. The mass spectrometer was operated in the positive ion mode. Each survey scan of m/z 400-2000 was followed by collision-assisted dissociation (CAD) MS/MS of twenty most intense precursor ions. Singly charged ions were excluded from CID selection. Normalized collision energies were employed using helium as the collision gas. MS/MS spectra were extracted from raw data files and converted into mgf files using a PAVA script (UCSF, MSF, San Francisco, CA). These mgf files were then independently searched against full length IgA1P database using an in-house Mascot TM server (Version 2.2.06, Matrix Science). Mass tolerances were 610 ppm for MS peaks, and 60.1 Da for MS/MS fragment ions. Trypsin specificity was used allowing for 1 missed cleavage. Met oxidation, proline hydroxylation, protein N-terminal acetylation, and peptide N-terminal pyroglutamic acid formation were allowed for variable modifications. Scaffold (version 4.3.2, Proteome Software, Portland, OR, USA) was used to validate MS/MS based peptide identifications. Peptide identifications were accepted if they could be established at greater than 95.0% probability as specified by the Peptide Prophet algorithm.
NMR and CD spectroscopy 15 N-HSQC spectra were recorded with a Varian 900 MHz NMR spectrometer (Rocky Mountain Regional 900 MHz NMR Facility at University of Colorado Denver Anschutz Medical Campus) at 308C in 50 mM Na 2 HPO 4 , pH 6.5, 150 mM NaCl and 6.7% D2O. NMR data were processed by NMRpipe 28 software package and analyzed using CCPNmr. 29 Far-UV CD measurements were conducted on a J815 spectrometer (Jasco, Easton, MD) using a 0.1 cm path length with six scans and the same buffer as used for NMR.
Protease activity assay
In the gel-based IgA1P activity assays, recombinant IgA1P proteins were incubated with substrate, IgA1 kappa (MyBioSource, San Diego, CA), for the indicated amount of time at room temperature in activity assay buffer (20 mM Tris, pH 7.4, 200 mM NaCl). The final concentrations of IgA1P and IgA1 substrate are 0.4 lM and 3.3 lM, respectively. The cleavage results were visualized by SDS-PAGE gel and coomassie stain. The ELISA-based protease activity assay proceeded as follows. IgA1 kappa antibody (3 nM) was incubated with different recombinant IgA1P proteins (0.1 nM) for 16 h at room temperature and the ELISA plates were coated with anti-human IgA1 Fc antibody at the same time. The IgA1P cleavage reactions were applied to the ELISA plates after the plates were blocked with blocking buffer (PBST with 0.5% BSA) for 2 h. Plates were washed three times with the wash buffer (PBST with 0.5% BSA). Either anti-kappa Ab or anti-Fc Ab was used for detection and the ratios of anti-kappa/anti-Fc were used to determine the percentage cleavage by the specific IgA1P constructs.
ELISA-based binding assay
ELISA plates were coated overnight at 48C with 100 lL of 150 nM of MBP-tag control, IgA1P 100, 20, or 4 ng/mL) were used in the same experimental setting described above and anti-IgA1 Fc antibody was used to detect the bound IgA1 Fc.
Immunoblotting assay
IgA1P positive and IgA1P negative S. pneumoniae were growth at 378C for 6 h before collecting the culture media and S. pneumoniae cells. The S. pneumoniae cultures were spin down at 2000 xg for 15 min at 48C and the S. pneumoniae cells were directly lysed in SDS sample buffer after removing the culture media. The culture media were collected and passed through 0.22 lM filters to further eliminate S. pneumoniae cells. The filtered media were then concentrated using centrifugal filter concentrator with 30 kDa molecular weight cut-off (Millipore, Billerica, MA). Five milliliters of culture media from either IgA1P positive or IgA1P negative were concentrated down to 100 lL and then mixed with SDS sample loading buffer at 1:1 ratio. All samples were heated to 1008C for 10 min before loading to SDS-PAGE. Proteins separated on SDS-PAGE were transferred to PVDF membranes, which were then probed with our anti-IgA1P antibody (in PBST with 3% skim milk) at room temperature for 1 h. After washing with PBST buffer three times, membrane was incubated with a HRP-conjugated anti-mouse secondary antibody at 1:5,000 dilution at room temperature for 1 h. The signal was developed with Pierce ECL western blotting substrates (Thermo Fisher Scientific, Grand Island, NY) and visualized using a ChemiDoc MP Imaging System (Bio-Rad, Hercules, CA).
